𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Prevalence characterization of extended-spectrum β-lactamases among Escherichia coli isolates collected in Zhengzhou

✍ Scribed by Zhijian Zhang; Xiaobing Guo; Qinxian Zhang


Publisher
John Wiley and Sons
Year
2009
Tongue
English
Weight
111 KB
Volume
23
Category
Article
ISSN
0887-8013

No coin nor oath required. For personal study only.

✦ Synopsis


Abstract

Objectives: To determine the prevalence and the diversity of extended‐spectrum β‐lactamases (ESBLs) among Escherichia coli isolates in Zhengzhou, China.

Methods: Clinical isolates were collected and investigated from the first affiliated hospital of Zhengzhou University and its associated health‐care facilities in Zhengzhou, China, during the period from January 2006 to June 2008. Antibiograms were performed on Mueller–Hinton agar plates with the disc‐diffusion method and MICs were determined by the agar‐dilution method. Total DNA was extracted with a Qiagen mini kit and screened by PCR.

Results: Of 94 nonduplicate ESBL‐positive isolates, TEM‐type was encoded in 74 and 79% of the ESBL isolates. Fifty‐six isolates were SHV type ESBLs. CTX‐M‐1, CTX‐M‐14, CTX‐M‐25, and CTX‐M‐38 types were encoded in 30, 54, 6, and 4, respectively. OXA‐1‐type β‐lactamases were encoded in six and OXA‐20‐type was encoded in two isolates.

Conclusions: We describe a complex ESBL epidemiology. The study revealed a high rate of ESBL‐producing E. coli isolates. TEM and CTX‐M enzymes dominated in ESBL‐positive E. coli isolates in Zhengzhou, China. J. Clin. Lab. Anal. 23:404–407, 2009. © 2009 Wiley‐Liss, Inc.


📜 SIMILAR VOLUMES


Activity in vitro of twelve antibiotics
✍ Antonio Sorlózano; José Gutiérrez; José María Romero; Juan de Dios Luna; Miguel 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 94 KB

## Abstract Twelve beta‐lactam and non‐beta‐lactam antibiotics were evaluated against 115 clinical isolates of extended‐spectrum beta‐lactamase‐producing (ESBLs) __Escherichia coli__ using a broth microdilution test in accordance with the CLSI guidelines. Susceptibility was 100% with imipenem, erta